Explore evidence

5.3 %Among 76 patients followed-up at endpoint, 5.3% (4/76) harbored HIV drug resistance.

CamerounVIH/sidaobserved 2009-2011published 2013PLoS ONEOpenAlexdocument of 8 observationsDOI 10.1371/journal.pone.0072680

23 %Among 110 HIV-1-infected, drug-naïve Cameroonians, 25 (23%) had unclassifiable protease (PR) sequences.

CamerounVIH/sidapublished 2002Journal of Clinical MicrobiologyOpenAlexdocument of 12 observations

0.92 probabilityThe survival probability was 0.92 at 12 months.

CamerounVIH/sidaobserved 12 monthspublished 2005Antiviral TherapyOpenAlexdocument of 8 observationsDOI 10.1177/135965350501000208

Systolic blood pressure was significantly increased with duration of highly active antiretroviral therapy (HAART) in HIV-infected Cameroonians.

CamerounVIH/sidapublished 2013Diabetes & metabolismeurope_pmcdocument of 12 observations

11 %The prevalence of the 376S substitution in reverse transcriptase sequences was 11% among 57 HIV-1-infected treatment-naive individuals from Cameroon.

CamerounVIH/sidapublished 2011AIDS Research and Human RetrovirusesOpenAlexdocument of 24 observations

77.9 %Including HIV indeterminate samples in test efficiency calculations significantly decreased specificities to a range from 77.9% to 98.0%.

CamerounVIH/sidapublished 2009PLoS ONEOpenAlexdocument of 3 observationsDOI 10.1371/journal.pone.0007702

19.6 %Ten out of 51 patients (19.6%) with NNRTI resistance accumulated mutations that may have compromised etravirine use.

CamerounVIH/sidapublished 2013Journal of the International AIDS Societyeurope_pmcdocument of 4 observations

67.7 %Viral suppression in the ART 48-60 group was 67.7%.

CamerounVIH/sidapublished 2018EClinicalMedicineOpenAlexdocument of 3 observationsDOI 10.1016/j.eclinm.2018.06.005